2022 Virtual Liver Journal Club

The program will educate hepatologists, gastroenterologists, oncologists, primary care physicians and
other health care providers involved in the management of patients with liver disease.

Topic: The role of immunotherapy as first line treatment for patients with primary liver
malignancies (hepatocellular carcinoma and HCC)

Directors:

Samer Tohme, MD
Assistant Professor in Transplant Surgery
UPMC Liver Cancer Center

Epameinondas Dogeas, MD
Surgical Oncology Fellow
UPMC Liver Cancer Center

Agenda:
6:00 p.m. Welcome and Introductions – Samer Tohme, MD
6:05 p.m. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable
Hepatocellular Carcinoma: A Meta-analysis – Epameinondas Dogeas, MD
6:20 p.m. Discussion
6:30 p.m. Snapshots from the recent ASCO meeting: – Epameinondas Dogeas, MD
HCC:
– Updated Results from the IMBRAVE150 trial
– HIMALYA Trial preliminary results
– LAUNCH trial
– COSMIC 312 study
Cholangiocarcinoma:
– TOPAZ-1 trial

6:50 p.m. Discussion
7:00 p.m. Adjourn

Register here: https://cvent.me/4323yO